Klin Farmakol Farm. 2026;40(1):47-55 | DOI: 10.36290/far.2026.002

QT interval, etiopathogenesis of "torsade de pointes", and risk pharmacotherapy

Přemysl Mladěnka1, Josef Kautzner2
1 Farmaceutická fakulta v Hradci Králové, Univerzita Karlova
2 Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

The electrocardiographic QT interval reflects the duration of ventricular depolarization and repolarization. Prolongation of the QT interval occurs most commonly due to a slowdown in the late repolarization phase. There are inherited forms of long QT syndrome caused by mutations in genes that encode components of potassium or sodium channels, with a prevalence of about 1 in 2000 inhabitants. Additionally, there are acquired forms of long QT syndrome, which often result from the use of certain medications. These drugs either directly block the potassium channel Kv11.1 (hERG), or disrupt its trafficking. Prolonged QT interval is a key risk factor for developing a type of polymorphic ventricular tachycardia known as torsade de pointes (TdP), which can lead to ventricular fibrillation. The relationship between QT interval and TdP is complex and is influenced by other risk factors, including bradycardia, existing cardiovascular disease and/or diabetes mellitus, hypokalaemia, and hypomagnesemia. Women have a higher risk due to a lower repolarization reserve. Several groups of medications are associated with QT interval prolongation and TdP, and they are shortly summarized in this paper. They include antiarrhythmic drugs, quinolones, macrolides, azole antimycotics, antimalarial drugs, antipsychotic medications, antidepressants, antihistamines, opioid analgesics, and some targeted anticancer therapies. Lastly, the treatment of TdP and strategies for the prevention of its development in inherited forms are discussed.

Keywords: QT interval, arrhythmia, dysrhythmia, torsade de pointes, hERG channel, late repolarization.

Received: November 7, 2025; Revised: January 12, 2026; Accepted: January 19, 2026; Published: April 20, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mladěnka P, Kautzner J. QT interval, etiopathogenesis of "torsade de pointes", and risk pharmacotherapy. Klin Farmakol Farm. 2026;40(1):47-55. doi: 10.36290/far.2026.002.
Download citation

References

  1. Lester RM, Paglialunga S, Johnson IA. QT Assessment in Early Drug Development: The Long and the Short of It. Int J Mol Sci. 2019;20(6):1324. Go to original source... Go to PubMed...
  2. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363-1372. Go to original source... Go to PubMed...
  3. Isbister GK. Risk assessment of drug-induced QT prolongation. Aust Prescr. 2015;38(1):20-24. Go to original source... Go to PubMed...
  4. Krahn AD, Laksman Z, Sy RW, et al. Congenital Long QT Syndrome. JACC Clin Electrophysiol. 2022;8(5):687-706. Go to original source... Go to PubMed...
  5. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is anti­arrhythmic. Circulation. 2001;103(15):2004-2013. Go to original source... Go to PubMed...
  6. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463-469. Go to original source... Go to PubMed...
  7. Vandenberg JI, Perry MD, Perrin MJ, et al. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev. 2012;92(3):1393-1478. Go to original source... Go to PubMed...
  8. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods. 2006;53(2):87-105. Go to original source... Go to PubMed...
  9. Nogawa H, Kawai T. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia. Eur J Pharmacol. 2014;741:336-339. Go to original source... Go to PubMed...
  10. van der Heyden MA, Smits ME, Vos MA. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol. 2008;153(3):406-409. Go to original source... Go to PubMed...
  11. Han S, Zhang Y, Chen Q, et al. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking. Eur J Pharmacol. 2011;650(1):138-144. Go to original source... Go to PubMed...
  12. Mladěnka P, Applová L, Patočka J, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018;38(4):1332-1403. Go to original source... Go to PubMed...
  13. Shah RR. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med. 2004;36(Suppl 1):47-52. Go to original source... Go to PubMed...
  14. Milon D, Daubert JC, Saint-Marc C, et al. Torsade de pointes. Apropos of 54 cases. Ann Fr Anesth Reanim. 1982;1(5):513-520. Go to original source... Go to PubMed...
  15. Hondeghem LM. Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation? Drug Saf. 2017. Go to original source... Go to PubMed...
  16. Tsuji Y, Yamazaki M, Shimojo M, et al. Mechanisms of torsades de pointes: an update. Front Cardiovasc Med. 2024;11:1363848. Go to original source... Go to PubMed...
  17. Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol. 2016;81(3):420-427. Go to original source... Go to PubMed...
  18. Chan A, Isbister GK, Kirkpatrick CM, et al. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100(10):609-615. Go to original source... Go to PubMed...
  19. Cyr S, Abdelaziz L, Minichiello A, et al. Impact of antidepressant and antipsychotic use in the occurence of torsades de pointes arrhythmia: a case-control study. Gen Hosp Psychiatry. 2025;94:16-23. Go to original source... Go to PubMed...
  20. Varro A, Baczko I. Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol. 2011;164(1):14-36. Go to original source... Go to PubMed...
  21. Obreztchikova MN, Sosunov EA, Plotnikov A, et al. Developmental changes in IKr and IKs contribute to age-related expression of dofetilide effects on repolarization and pro­arrhythmia. Cardiovasc Res. 2003;59(2):339-350. Go to original source... Go to PubMed...
  22. Yokohara S, Hashiguchi M, Shiga T. Psychotherapeutic drug-induced life-threatening arrhythmias: A retrospective analysis using the Japanese adverse drug event report database. J Arrhythm. 2023;39(6):928-936. Go to original source... Go to PubMed...
  23. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96(7):2149-2154. Go to original source... Go to PubMed...
  24. Shaffer D, Singer S, Korvick J, et al. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35(2):197-200. Go to original source... Go to PubMed...
  25. Orlandi C. A case of torsade de pointes caused by hypomagnesemia. G Ital Cardiol. 1986;16(12):1062-1065.
  26. Pasławska U, Noszczyk-Nowak A, Kungl K, et al. Thyroid hormones concentrations and ECG picture in the dog. Pol J Vet Sci. 2006;9(4):253-257.
  27. Corović N, Duraković Z, Misigoj-Duraković M. Dispersion of the corrected QT and JT interval in the electrocardiogram of alcoholic patients. Alcohol Clin Exp Res. 2006;30(1):150-154. Go to original source... Go to PubMed...
  28. Cunha DF, Cunha SF, Ferreira TP, et al. Prolonged QTc intervals on the electrocardiograms of hospitalized malnourished adults. Nutrition. 2001;17(5):370-372. Go to original source... Go to PubMed...
  29. Astrom-Lilja C, Odeberg JM, Ekman E, et al. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17(6):587-592. Go to original source... Go to PubMed...
  30. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur Heart J Suppl. 2001;3(Suppl K):K70-80. Go to original source...
  31. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259(1):59-69. Go to original source... Go to PubMed...
  32. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. Go to original source... Go to PubMed...
  33. Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev. 2002;21(4):189-203. Go to original source... Go to PubMed...
  34. Liu Y, Xue Y, Wu S, et al. Effect of verapamil in the treatment of type 2 long QT syndrome is not a dose-dependent pattern: a study from bedside to bench, and back. Eur Heart J Suppl. 2016;18(suppl_A):A37-A46. Go to original source...
  35. Milberg P, Reinsch N, Osada N, et al. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005;100(4):365-371. Go to original source... Go to PubMed...
  36. Taglialatela M, Castaldo P, Pannaccione A, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy. 1999;29(Suppl 3):182-189. Go to original source... Go to PubMed...
  37. Olasinska-Wisniewska A, Olasinski J, Grajek S. Cardiovascular safety of antihistamines. Postepy Dermatol Alergol. 2014;31(3):182-186. Go to original source... Go to PubMed...
  38. Hagiwara T, Satoh S, Kasai Y, et al. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol. 2001;87(3):231-234. Go to original source...
  39. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011;120(2):103-110. Go to original source... Go to PubMed...
  40. Abo-Salem E, Fowler JC, Attari M, et al. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther. 2014;32(1):19-25. Go to original source... Go to PubMed...
  41. Brunetti L, Lee SM, Nahass RG, et al. The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone. Int J Infect Dis. 2019;78:50-56. Go to original source... Go to PubMed...
  42. Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther. 2002;302(1):320-327. Go to original source... Go to PubMed...
  43. Hancox JC, Hasnain M, Vieweg WV, et al. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1(5):155-165. Go to original source... Go to PubMed...
  44. Albert RK, Schuller JL. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med. 2014;189(10):1173-1180. Go to original source... Go to PubMed...
  45. Gysel M, Vieweg WV, Hasnain M, et al. Torsades de pointes following clarithromycin treatment. Expert Rev Cardiovasc Ther. 2013;11(11):1485-1493. Go to original source... Go to PubMed...
  46. Brown SM, Peltan I, Kumar N, et al. Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial. Ann Am Thorac Soc. 2021;18(4):590-597. Go to original source... Go to PubMed...
  47. Farmakis IT, Minopoulou I, Giannakoulas G, et al. Cardiotoxicity of azithromycin in COVID-19: an overall proportion meta-analysis. Adv Respir Med. 2022;90(3). Go to original source... Go to PubMed...
  48. Sung DJ, Kim JG, Won KJ, et al. Blockade of K+ and Ca2+ channels by azole antifungal agents in neonatal rat ventricular myocytes. Biol Pharm Bull. 2012;35(9):1469-1475. Go to original source... Go to PubMed...
  49. von Heeren F, Tanner R, Theurillat R, et al. Determination of fluconazole in human plasma by micellar electrokinetic capillary chromatography with detection at 190 nm. Journal of Chromatography A. 1996;745(1):165-172. Go to original source... Go to PubMed...
  50. Santos SR, Campos EV, Sanches C, et al. Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients. Clinics (Sao Paulo). 2010;65(2):237-243. Go to original source... Go to PubMed...
  51. Salem M, Reichlin T, Fasel D, et al. Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports. Glob Cardiol Sci Pract. 2017;2017(2):11. Go to original source... Go to PubMed...
  52. Haeusler IL, Chan XHS, Guérin PJ, et al. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med. 2018;16(1):200. Go to original source... Go to PubMed...
  53. Funck-Brentano C, Ouologuem N, Duparc S, et al. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Scientific Reports. 2019;9(1):883. Go to original source... Go to PubMed...
  54. Buckingham R. Martindale. The complete drug reference. 40th edition. London (UK): Pharmaceutical Press; 2020.
  55. Traebert M, Dumotier B. Antimalarial drugs: QT prolongation and cardiac arrhythmias. Expert Opin Drug Saf. 2005;4(3):421-431. Go to original source... Go to PubMed...
  56. Bouchaud O, Imbert P, Touze JE, et al. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J. 2009;8:289. Go to original source... Go to PubMed...
  57. Millat-Martínez P, Salman S, Moore BR, et al. Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine. Anti­microb Agents Chemother. 2022;66(8):e0018522. Go to original source... Go to PubMed...
  58. Esposito S, Bianchini S, Blasi F. Bedaquiline and delamanid in tuberculosis. Expert Opin Pharmacother. 2015;16(15):2319-2330. Go to original source... Go to PubMed...
  59. Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50(5). Go to original source... Go to PubMed...
  60. Kwon YS, Jeong BH, Koh WJ. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Expert Opin Pharmacother. 2015;16(2):253-261. Go to original source... Go to PubMed...
  61. Anand AB, Malur K, Sabnis GR, et al. A case series of drug-induced torsades de pointes in patients on multidrug-resistant tuberculosis treatment: Beware the gift that conceals a blade. Heart Rhythm O2. 2024;5(5):324-326. Go to original source... Go to PubMed...
  62. Le Blaye I, Donatini B, Hall M, et al. Acute overdosage with thioridazine: a review of the available clinical exposure. Vet Hum Toxicol. 1993;35(2):147-150.
  63. Isbister GK, Balit CR, Macleod D, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol. 2010;30(4):391-395. Go to original source... Go to PubMed...
  64. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108(41):687-693. Go to original source... Go to PubMed...
  65. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol. Am J Ther. 2003;10(1):58-60. Go to original source... Go to PubMed...
  66. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology. 2007;107(4):531-536. Go to original source... Go to PubMed...
  67. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg. 1994;79(5):983-986. Go to original source... Go to PubMed...
  68. Tampi RR, Balderas M, Carter KV, et al. Citalopram, QTc Prolongation, and Torsades de Pointes. Psychosomatics. 2015;56(1):36-43. Go to original source... Go to PubMed...
  69. Kumar S, Gayle JA, Mogalapalli A, et al. Escitalopram Induced Torsade de Pointes and Cardiac Arrest in a Patient With Surgically Treated Mitral Valve Prolapse. Cureus. 2020;12(12):e11960. Go to original source... Go to PubMed...
  70. Lingyan G, Dongdong Z, Sang G, et al. Escitalopram-induced prolongation of QT interval and Torsades de Pointes. Adverse Drug Reactions Journal. 2020;22(12):695-696.
  71. de Meester A, Carbutti G, Gabriel L, et al. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56(4):258-261. Go to original source... Go to PubMed...
  72. Khederlou H, Azimi Pirsaraei V. Torsades de Pointe Associated with Trazodone Consumption Case Rep Crit Care. 2024;2024:5759229. Go to original source... Go to PubMed...
  73. Giroski L, Shih R. QTC Prolongation and Torsades in Bupropion Overdoses Presenting to United States Emergency Departments. Journal of Emergency Medicine. 2012;43(5):934-935. Go to original source...
  74. Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother. 2003; 37(7-8):999-1002. Go to original source... Go to PubMed...
  75. Raffa RB, Burmeister JJ, Yuvasheva E, et al. QTc interval prolongation by d-propoxyphene: what about other analgesics? Expert Opin Pharmacother. 2012;13(10):1397-1409. Go to original source... Go to PubMed...
  76. Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77(2):205-223. Go to original source... Go to PubMed...
  77. Alinejad S, Kazemi T, Zamani N, et al. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577-600.
  78. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166(12):1280-1287. Go to original source... Go to PubMed...
  79. Duthie DJ, McLaren AD, Nimmo WS. Pharmacokinetics of fentanyl during constant rate i.v. infusion for the relief of pain after surgery. Br J Anaesth. 1986;58(9):950-956. Go to original source... Go to PubMed...
  80. Cicci JD, Jagielski SM, Clarke MM, et al. Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report. Eur Heart J Case Rep. 2019;3(4):1-6. Go to original source... Go to PubMed...
  81. Marzec LN, Katz DF, Peterson PN, et al. Torsade de Pointes Associated with High-dose Loperamide Ingestion. J Innov Card Rhythm Manag. 2015;6(1):1897-1999.
  82. Cirillo I, Ariyawansa J, Ali SR, et al. Effect of loperamide on heart rhythm: Randomized, double-blind, controlled study in healthy adults. JAPhA Pharmacotherapy. 2024;1(3):100006. Go to original source...
  83. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295-316. Go to original source... Go to PubMed...
  84. Megías-Vericat JE, Solana-Altabella A, Ballesta-López O, et al. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol. 2020;99(9):1989-2007. Go to original source... Go to PubMed...
  85. Anand K, Ensor J, Trachtenberg B, et al. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol. 2019;1(2):172-178. Go to original source... Go to PubMed...
  86. Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. Go to original source... Go to PubMed...
  87. Kang D, Ludwig E, Jaworowicz D, et al. Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2021;87(4):513-523. Go to original source... Go to PubMed...
  88. Loffi M, Toffetti L, Gianni C, et al. Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes. J Cardiovasc Electrophysiol. 2015;26(7):811-813. Go to original source... Go to PubMed...
  89. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the Euro­pean Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. Go to original source... Go to PubMed...
  90. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29(15):2052-2059. Go to original source... Go to PubMed...
  91. Shetty N, Gupta S. Eribulin drug review. South Asian J Can­cer. 2014;3(1):57-59. Go to original source... Go to PubMed...
  92. Fostvedt LK, Shaik N, Martinelli G, et al. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. Expert Rev Clin Pharmacol. 2021;14(7):927-935. Go to original source... Go to PubMed...
  93. Vogel CL, Johnston MA, Capers C, et al. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer. 2014;14(1):1-9. Go to original source... Go to PubMed...
  94. Flatman PW, Lew VL. The magnesium dependence of sodium-pump-mediated sodium-potassium and sodium-sodium exchange in intact human red cells. J Physiol. 1981;315:421-446. Go to original source... Go to PubMed...
  95. Apell HJ, Hitzler T, Schreiber G. Modulation of the Na,K-ATPase by Magnesium Ions. Biochemistry. 2017;56(7):1005-1016. Go to original source... Go to PubMed...
  96. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011;124(20):2181-2184. Go to original source... Go to PubMed...
  97. Khatib R, Sabir FRN, Omari C, et al. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452-458. Go to original source... Go to PubMed...
  98. Magyar J, Horváth B, Bányász T, et al. L-364,373 fails to activate the slow delayed rectifier K+ current in canine ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(1):85-89. Go to original source... Go to PubMed...
  99. Short B. A range of activators for cardiac IKs channels J Gen Physiol. 2020;152(2). Go to original source... Go to PubMed...
  100. Corici C, Kohajda Z, Kristóf A, et al. L-364,373 (R-L3) enantiomers have opposite modulating effects on IKs in mammalian ventricular myocytes. Can J Physiol Pharmacol. 2013;91(8):586-592. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.